Screening for ovarian cancer: recommendation statement.
出版信息
Ann Fam Med. 2004 May-Jun;2(3):260-2. doi: 10.1370/afm.200.
Abstract
摘要
相似文献
1
Screening for ovarian cancer: recommendation statement.
Ann Fam Med. 2004 May-Jun;2(3):260-2. doi: 10.1370/afm.200.
2
Personalizing ovarian cancer screening.
J Natl Cancer Inst. 2010 Aug 4;102(15):1112-3. doi: 10.1093/jnci/djq296. Epub 2010 Jul 28.
3
Screening for ovarian cancer.
Med J Aust. 1995 Apr 17;162(8):396. doi: 10.5694/j.1326-5377.2003.tb05399.x.
4
A step forward for two-step screening for ovarian cancer.
J Clin Oncol. 2010 May 1;28(13):2128-30. doi: 10.1200/JCO.2009.26.6346. Epub 2010 Apr 5.
5
Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.
Ann Intern Med. 2012 Dec 18;157(12):900-4. doi: 10.7326/0003-4819-157-11-201212040-00539.
6
Summaries for patients. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.
Ann Intern Med. 2012 Dec 18;157(12):I-56. doi: 10.7326/0003-4819-157-11-201212040-00540.
7
Screening of symptomatic women for ovarian cancer.
Lancet Oncol. 2012 Apr;13(4):e137; author reply e139-40. doi: 10.1016/S1470-2045(12)70104-3. Epub 2012 Mar 30.
8
Screening of symptomatic women for ovarian cancer.
Lancet Oncol. 2012 Apr;13(4):e137-8; author reply e139-40. doi: 10.1016/S1470-2045(12)70149-3. Epub 2012 Mar 30.
9
By the way, doctor. I received a widely circulated e-mail message about use of the CA-125 blood test in screening for ovarian cancer. The message suggested that the CA-125 test be used for routine screening, like a Pap smear. Do you agree? What's your opinion of this test?
Harv Womens Health Watch. 2001 Jul;8(11):8.
10
[Mass-screening for ovarian cancer].
Nihon Rinsho. 2004 Oct;62 Suppl 10:601-4.
引用本文的文献
1
Cancer of the ovary, fallopian tube, and peritoneum: 2025 update.
Int J Gynaecol Obstet. 2025 Sep;171 Suppl 1:6-35. doi: 10.1002/ijgo.70282.
2
Clinical Practice Guidelines on Menopause: *An Executive Summary and Recommendations: Indian Menopause Society 2019-2020.
J Midlife Health. 2020 Apr-Jun;11(2):55-95. doi: 10.4103/jmh.JMH_137_20. Epub 2020 Aug 10.
3
Dysregulated expression of long noncoding RNAs in gynecologic cancers.
Mol Cancer. 2017 Jun 21;16(1):107. doi: 10.1186/s12943-017-0671-2.
4
[A retrospective study of ovarian cancer with a median follow of 42 months].
Pan Afr Med J. 2015 Mar 9;20:211. doi: 10.11604/pamj.2015.20.211.6113. eCollection 2015.
5
Immunohistochemical staining of tumor necrosis factor-α and interleukin-10 in benign and malignant ovarian neoplasms.
Oncol Lett. 2015 Feb;9(2):979-983. doi: 10.3892/ol.2014.2781. Epub 2014 Dec 8.
6
Ovarian cancer screening practices of obstetricians and gynecologists in puerto rico.
Biomed Res Int. 2014;2014:920915. doi: 10.1155/2014/920915. Epub 2014 Jun 5.
7
Prophylactic bilateral oophorectomy at time of hysterectomy for women at low risk: acog revises practice guidelines for ovarian cancer screening in low-risk women.
Curr Oncol. 2014 Feb;21(1):9-12. doi: 10.3747/co.21.1721.
8
Biomarker testing for ovarian cancer: clinical utility of multiplex assays.
Mol Diagn Ther. 2013 Jun;17(3):139-46. doi: 10.1007/s40291-013-0027-6.
9
Current recommendations for cervical cancer screening: do they render the annual pelvic examination obsolete?
Med Princ Pract. 2013;22(4):313-22. doi: 10.1159/000346137. Epub 2013 Jan 15.
10
Routine bimanual pelvic examinations: practices and beliefs of US obstetrician-gynecologists.
Am J Obstet Gynecol. 2013 Feb;208(2):109.e1-7. doi: 10.1016/j.ajog.2012.11.015. Epub 2012 Nov 22.
本文引用的文献
1
The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer.
Gynecol Oncol. 2002 Dec;87(3):237-9. doi: 10.1006/gyno.2002.6865.
2
Menopausal hormone replacement therapy and risk of ovarian cancer.
JAMA. 2002 Jul 17;288(3):334-41. doi: 10.1001/jama.288.3.334.
3
Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women.
JAMA. 2001 Mar 21;285(11):1460-5. doi: 10.1001/jama.285.11.1460.
4
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S. doi: 10.1016/s0197-2456(00)00098-2.
5
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.
Control Clin Trials. 2000 Dec;21(6 Suppl):251S-272S. doi: 10.1016/s0197-2456(00)00097-0.
6
Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography.
Cancer. 2000 Aug 1;89(3):582-8. doi: 10.1002/1097-0142(20000801)89:3<582::aid-cncr13>3.0.co;2-#.
7
The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.
Gynecol Oncol. 2000 Jun;77(3):350-6. doi: 10.1006/gyno.2000.5816.
8
Screening for ovarian cancer: a pilot randomised controlled trial.
Lancet. 1999 Apr 10;353(9160):1207-10. doi: 10.1016/S0140-6736(98)10261-1.
9
Screening for ovarian cancer: a systematic review.
Health Technol Assess. 1998;2(2):i-iv, 1-84.
10
A combined approach for the early detection of ovarian cancer in asymptomatic women.
Eur J Obstet Gynecol Reprod Biol. 1996 Apr;65(2):221-5. doi: 10.1016/0301-2115(95)02369-0.
Zotero 插件